- Home
- MUA vs LXRX Comparison
MUA vs LXRX Comparison
Compare MUA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- LXRX
- Stock Information
- Founded
- MUA 1993
- LXRX 1995
- Country
- MUA United States
- LXRX United States
- Employees
- MUA N/A
- LXRX N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- LXRX Health Care
- Exchange
- MUA Nasdaq
- LXRX Nasdaq
- Market Cap
- MUA 407.1M
- LXRX 428.8M
- IPO Year
- MUA N/A
- LXRX 2000
- Fundamental
- Price
- MUA $11.79
- LXRX $1.15
- Analyst Decision
- MUA
- LXRX Buy
- Analyst Count
- MUA 0
- LXRX 5
- Target Price
- MUA N/A
- LXRX $3.23
- AVG Volume (30 Days)
- MUA 92.6K
- LXRX 1.7M
- Earning Date
- MUA 01-01-0001
- LXRX 11-11-2025
- Dividend Yield
- MUA 4.84%
- LXRX N/A
- EPS Growth
- MUA N/A
- LXRX N/A
- EPS
- MUA N/A
- LXRX N/A
- Revenue
- MUA N/A
- LXRX $58,432,000.00
- Revenue This Year
- MUA N/A
- LXRX N/A
- Revenue Next Year
- MUA N/A
- LXRX N/A
- P/E Ratio
- MUA N/A
- LXRX N/A
- Revenue Growth
- MUA N/A
- LXRX 1504.83
- 52 Week Low
- MUA $8.61
- LXRX $0.28
- 52 Week High
- MUA $11.43
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- MUA 89.24
- LXRX 54.28
- Support Level
- MUA $10.58
- LXRX $1.03
- Resistance Level
- MUA $10.74
- LXRX $1.15
- Average True Range (ATR)
- MUA 0.17
- LXRX 0.06
- MACD
- MUA 0.10
- LXRX -0.00
- Stochastic Oscillator
- MUA 100.00
- LXRX 70.59
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.